CN101621991A - 降钙素的口服施用 - Google Patents

降钙素的口服施用 Download PDF

Info

Publication number
CN101621991A
CN101621991A CN200880006790A CN200880006790A CN101621991A CN 101621991 A CN101621991 A CN 101621991A CN 200880006790 A CN200880006790 A CN 200880006790A CN 200880006790 A CN200880006790 A CN 200880006790A CN 101621991 A CN101621991 A CN 101621991A
Authority
CN
China
Prior art keywords
amount
calcitonin
minutes
liquid
peptide drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880006790A
Other languages
English (en)
Chinese (zh)
Inventor
Y·乔希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN201710436918.4A priority Critical patent/CN107050433A/zh
Publication of CN101621991A publication Critical patent/CN101621991A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
CN200880006790A 2007-03-02 2008-02-29 降钙素的口服施用 Pending CN101621991A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710436918.4A CN107050433A (zh) 2007-03-02 2008-02-29 降钙素的口服施用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89259407P 2007-03-02 2007-03-02
US60/892,594 2007-03-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710436918.4A Division CN107050433A (zh) 2007-03-02 2008-02-29 降钙素的口服施用

Publications (1)

Publication Number Publication Date
CN101621991A true CN101621991A (zh) 2010-01-06

Family

ID=39496395

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880006790A Pending CN101621991A (zh) 2007-03-02 2008-02-29 降钙素的口服施用
CN201710436918.4A Pending CN107050433A (zh) 2007-03-02 2008-02-29 降钙素的口服施用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710436918.4A Pending CN107050433A (zh) 2007-03-02 2008-02-29 降钙素的口服施用

Country Status (16)

Country Link
US (1) US8410052B2 (https=)
EP (1) EP2131810B1 (https=)
JP (1) JP5249246B2 (https=)
KR (2) KR20150091536A (https=)
CN (2) CN101621991A (https=)
AT (1) ATE507818T1 (https=)
AU (1) AU2008223108B2 (https=)
BR (1) BRPI0808517A2 (https=)
CA (1) CA2679782C (https=)
DE (1) DE602008006700D1 (https=)
ES (1) ES2365648T3 (https=)
MX (1) MX2009009243A (https=)
PL (1) PL2131810T3 (https=)
PT (1) PT2131810E (https=)
RU (2) RU2009136303A (https=)
WO (1) WO2008109385A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104487056A (zh) * 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
CN104961687A (zh) * 2015-06-03 2015-10-07 苏州维泰生物技术有限公司 1,2-二嗪衍生物及其制剂、用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
GEP201606523B (en) * 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
EP3542790B1 (en) 2012-03-22 2023-09-13 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
CN115884959A (zh) * 2020-04-22 2023-03-31 耶路撒冷希伯来大学伊森姆研究发展有限公司 生物活性的苯酚盐离子络合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
WO2000059480A1 (en) 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
EP1420827B8 (en) 2001-08-17 2009-12-23 Novartis AG 5-cnac as oral delivery agent for parathyroid hormone fragments
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
PE20040724A1 (es) * 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
MXPA06000807A (es) * 2003-07-23 2006-08-23 Novartis Ag Uso de calcitonina en osteoartritis.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104487056A (zh) * 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
CN104961687A (zh) * 2015-06-03 2015-10-07 苏州维泰生物技术有限公司 1,2-二嗪衍生物及其制剂、用途
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途

Also Published As

Publication number Publication date
ES2365648T3 (es) 2011-10-07
RU2013150659A (ru) 2015-05-20
US20100210526A1 (en) 2010-08-19
JP5249246B2 (ja) 2013-07-31
CN107050433A (zh) 2017-08-18
ATE507818T1 (de) 2011-05-15
KR20150091536A (ko) 2015-08-11
PT2131810E (pt) 2011-08-03
MX2009009243A (es) 2009-09-08
EP2131810B1 (en) 2011-05-04
DE602008006700D1 (https=) 2011-06-16
PL2131810T3 (pl) 2011-09-30
AU2008223108B2 (en) 2013-10-10
EP2131810A2 (en) 2009-12-16
KR20090116772A (ko) 2009-11-11
AU2008223108A2 (en) 2009-09-10
CA2679782A1 (en) 2008-09-12
CA2679782C (en) 2015-02-17
BRPI0808517A2 (pt) 2014-08-19
WO2008109385A2 (en) 2008-09-12
US8410052B2 (en) 2013-04-02
JP2010520221A (ja) 2010-06-10
AU2008223108A1 (en) 2008-09-12
WO2008109385A3 (en) 2009-04-09
KR101564114B1 (ko) 2015-10-28
RU2009136303A (ru) 2011-04-10

Similar Documents

Publication Publication Date Title
CN101621991A (zh) 降钙素的口服施用
RU2287999C2 (ru) Фармацевтические композиции для перорального введения фармакологически действующих веществ
US7569539B2 (en) Oral administration of calcitonin
RU2493868C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
AU2005202705B2 (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
HK1059565B (en) Pharmaceutical compositions for the oral delivery of calcitonin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100106